Pfizer Wins Approval for Drug to Treat Type of Leukemia
This article is for subscribers only.
Pfizer Inc., the world’s largest drugmaker, won U.S. regulatory approval of its treatment for one of the four most common types of leukemia.
The Food and Drug Administration cleared the drug, to be known as Bosulif, for adults with previously treated chronic myeloid leukemia who also have an abnormality known as the Philadelphia chromosome, the New York-based company said today in a statement. There are expected to be about 5,400 new cases and 610 deaths from the blood cancer this year, according to the American Cancer Society in Atlanta.